bluebird proposes $600M follow-on after ASH gains

bluebird bio Inc. (NASDAQ:BLUE) jumped $30.65 (18%) to $201.80 on Monday, adding over $1.4 billion in market cap, after reporting updated data from the Phase I CRB-401 trial evaluating its chimeric